National Cancer Institute (NCI)s

National Cancer Institute (NCI)

444 Protocols (228 Active Accrual of new subjects, 216 Follow-up of previously enrolled subjects)

 10-C-0201:

Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency

 10-C-0166:

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

 10-C-0086:

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

 10-C-0066:

A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment

 09-C-0242:

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

 09-C-0161:

Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

 09-C-0053:

Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don

 07-C-0100:

Collection of Blood from Patients with Prostate Cancer

 06-C-0213:

Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)

 06-C-0014:

Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies

 04-C-0281:

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

 04-C-0274:

Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents

 04-C-0200:

Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

 04-C-0165:

Data Collection, Clinical Care and Interventions in CCR, NCI

 04-C-0102:

Hematologic Malignancy Biology Study

 03-C-0277:

Cell Harvest and Preparation for Surgery Branch Treatment Protocols

 03-C-0066:

Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer

 02-C-0211:

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

 02-C-0179:

Biospecimen Acquisition from Human Subjects

 02-C-0159:

Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts

 02-C-0064:

Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy

 02-C-0052:

Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study

 01-C-0038:

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer

 00-C-0074:

Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy

 99-C-0128:

Evaluation for NCI Surgery Branch Clinical Research Protocols

 97-C-0147:

Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases

 89-C-0086:

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

 83-C-0022:

Psychological Benefits of a Normalized Camping Experience for Children with Cancer

 002191-C:

A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.

 002095-C:

Phase II Trial of Alpelisib with iNOS Inhibitor and Nab-paclitaxel in Patients with HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)

 002068-C:

Phase II Pilot Study of Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

 001969-C:

A Phase 3 Trial of PRGN-2012 Treatment of Recurrent Respiratory Papillomatosis in Adult Patients

 001948-C:

Evaluation of Efficacy & Immune-Related Adverse Events and Patient-Reported Symptoms Associated with Immunotherapies: MD Anderson Cancer Center Efforts for Advanced Mechanistic, Clinical and Translational Science

 001891-C:

An Exploratory Study Using a Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

 001826-C:

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems using Pupillometry in Participants with Neurofibromatosis Type 1 (NF1)

 001805-C:

Long-Term Follow Up for Subjects Treated with Gene Therapy Cell Products at Rutgers Cancer Institute

 001718-C:

Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

 001704-C:

Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma

 001609-C:

Phase I/II Study of Neoadjuvant Inhaled Azacytidine with Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

 001605-C:

Phase II Study of Alrizomadlin (APG-115) in Subjects with BAP1 Cancer Syndrome and Early-Stage Mesothelioma

 001591-C:

Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors

 001590-C:

Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab plus Atezolizumab

 001589-C:

A Phase II Study of Immunotherapies (Tiragolumab and Atezolizumab) in Combination with Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

 001578-C:

A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

 001571-C:

A Phase I Study of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Cervix, and Lung

 001554-C:

Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

 001549-C:

Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects with BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

 001541-C:

A Phase I/II Trial of Eltanexor (KPT-8602) with Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

 001536-C:

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 with Pembrolizumab before Standard Treatment in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal Cancer

 001533-C:

A Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

 001531-C:

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation with Briquilimab-Based Conditioning in Participants with GATA2 Deficiency

 001524-C:

A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies

 001092-C:

Exploring the Role of Palliative Care in Phase 1 Enrolled Pediatric Oncology Patients

 001004-C:

A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer

 000954-C:

A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer

 000930-C:

A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer

 000692-C:

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide

 000633-C:

Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

 000596-C:

Phase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell Carcinoma

 000569-C:

Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy

 000520-C:

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

 000516-C:

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System

 000484-C:

Randomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior Bevacizumab

 000475-C:

Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)

 000462-C:

Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma

 000423-C:

Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults with Sickle Cell Disease (SCD): A Pilot Randomized Controlled Trial

 000356-C:

A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes

 000328-C:

Bicalutamide Implants (Biolen ) with Radiation Therapy in Patients with Localized Prostate Cancer

 000305-C:

Exploratory Phase II Study of LAnreotide in Unresectable or Metastatic Pheochromocytoma / PARAganglioma

 000293-C:

Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed with a Primary Central Nervous System Tumor

 000254-C:

A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

 000251-C:

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

 000237-C:

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

 000194-C:

A Phase I Trial of ProAgio, an anti- alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

 000178-C:

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

 000115-C:

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D

 000096-C:

A Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck Cancer

 000085-C:

Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: An Observational Study

 000081-C:

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

 000080-C:

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

 000067-C:

Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy

 000045-C:

A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial Cancers

 000030-C:

Phase 2 Study of Bintrafusp alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON)

 21-C-0032:

GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure

 21-C-0024:

A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

 21-C-0022:

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR(TM) T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

 21-C-0015:

Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma

 21-C-0013:

A Phase I/II Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis

 21-C-0007:

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

 20-C-0167:

Close Assessment and Testing for Chronic Graft-vs-Host Disease (CATCH Study)

 20-C-0155:

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)

 20-C-0154:

Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors

 20-C-0150:

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

 20-C-0149:

Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

 20-C-0142:

A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial Carcinoma

 20-C-0138:

Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal Cancers

 20-C-0130:

A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain

 20-C-0127:

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

 20-C-0104:

Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive Cancers

 20-C-0065:

A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients

Previous 100 Protocols

Next -300 Protocols